RxDoctor Payments Data

Jon Beacher, MD

Pulmonary Disease · Gainesville, FLNPI 1457341778

Payments from drug & device makers

$1,345in general payments, 2019–2025

Across 60 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$470
  • AstraZeneca$334
  • Pulmonx Corporation$216
  • Amgen$154
  • ANI Pharmaceuticals, Inc.$100
  • Insmed, Inc.$72

What the payments were for

  • Food & beverage$1,345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK23$470
AstraZeneca17$334
Pulmonx Corporation7$216
Amgen7$154
ANI Pharmaceuticals, Inc.3$100
Insmed, Inc.3$72

How this compares

$1,345 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$143,929
Medicare patients
408
Services billed
1,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter406$312,618
Breo ElliptaFluticasone/Vilanterol36$26,317
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$18,912
Fluticasone-SalmeterolFluticasone Propion/Salmeterol88$13,754
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$11,731
Wixela InhubFluticasone Propion/Salmeterol88$9,317
Albuterol Sulfate HfaAlbuterol Sulfate326$6,590
Combivent RespimatIpratropium/Albuterol Sulfate11$5,791
SymbicortBudesonide/Formoterol Fumarate17$3,936
Arnuity ElliptaFluticasone Furoate15$3,361
Fluticasone Propionate HfaFluticasone Propionate11$2,801
Advair DiskusFluticasone Propion/Salmeterol11$2,757
Ventolin HfaAlbuterol Sulfate37$1,970
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,648
Pantoprazole Sodium16$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$470$354,027472 claims
AstraZenecaBreztri Aerosphere, Symbicort$334$22,84847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →